Dompe to pay $32 million over Medicare co-pay scheme for eye drug
Dompe U.S. Inc., the American subsidiary of Italy-based Dompe farmaceutici S.p.A., has agreed to pay $32 million to resolve allegations that it violated the Anti-Kickback Statute and the False Claims Act, the Justice Department announced.
TL;DR
- Dompe U.S. Inc. will pay $32 million.
- The settlement resolves allegations of violating the Anti-Kickback Statute and the False Claims Act.
- Dompe U.S. Inc. is the American subsidiary of Italy-based Dompe farmaceutici S.p.A.
- The allegations concern a scheme involving Medicare co-pays for an eye drug.